Critical Path Institute (C-Path) announced today that Sanofi, a global leader in immunology and diabetes care, has joined its Type 1 Diabetes Consortium (T1DC) The consortium achieves this by fostering collaborative relationships within the broader T1D community and sharing data, knowledge and resources to promote the development and regulatory endorsement of novel drug development tools .